Notes
The study was sponsored by Baxalta, a member of the Takeda group of companies.
Reference
Hu X, et al. The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. Health Economics Review : 29 Dec 2019. Available from: URL: https://doi.org/10.1186/s13561-019-0257-3
Rights and permissions
About this article
Cite this article
Pegaspargase preferred option in acute lymphoblastic leukaemia. PharmacoEcon Outcomes News 844, 30 (2020). https://doi.org/10.1007/s40274-020-6493-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6493-2